about
Innate Immunity and Inflammation Post-Stroke: An α7-Nicotinic Agonist PerspectiveMolecular recognition of the neurotransmitter acetylcholine by an acetylcholine binding protein reveals determinants of binding to nicotinic acetylcholine receptorsSynthesis, pharmacology, and biostructural characterization of novel α4β2 nicotinic acetylcholine receptor agonistsAcetylcholine-Binding Protein Engineered to Mimic the α4-α4 Binding Pocket in α4β2 Nicotinic Acetylcholine Receptors Reveals Interface Specific Interactions Important for Binding and ActivityStructural and functional studies of the modulator NS9283 reveal agonist-like mechanism of action at α4β2 nicotinic acetylcholine receptorsExploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for α(1)-adrenoceptors.Ligand Binding at the 4-4 Agonist-Binding Site of the 42 nAChR Triggers Receptor Activation through a Pre-Activated Conformational State.Covalent trapping of methyllycaconitine at the α4-α4 interface of the α4β2 nicotinic acetylcholine receptor: antagonist binding site and mode of receptor inhibition revealed.Probing the orthosteric binding site of GABAA receptors with heterocyclic GABA carboxylic acid bioisosteres.Revision of the classical dopamine D2 agonist pharmacophore based on an integrated medicinal chemistry, homology modelling and computational docking approach.GABAA receptor partial agonists and antagonists: structure, binding mode, and pharmacology.Structural Studies of Nicotinic Acetylcholine Receptors: Using Acetylcholine-Binding Protein as a Structural Surrogate.Radiosynthesis and evaluation of new α1-adrenoceptor antagonists as PET radioligands for brain imaging.Tying up Nicotine: New Selective Competitive Antagonist of the Neuronal Nicotinic Acetylcholine Receptors.Exploration of the molecular architecture of the orthosteric binding site in the α4β2 nicotinic acetylcholine receptor with analogs of 3-(dimethylamino)butyl dimethylcarbamate (DMABC) and 1-(pyridin-3-yl)-1,4-diazepane.Pinnatoxins E, F and G target multiple nicotinic receptor subtypes.Two distinct allosteric binding sites at α4β2 nicotinic acetylcholine receptors revealed by NS206 and NS9283 give unique insights to binding activity-associated linkage at Cys-loop receptors.Docking to flexible nicotinic acetylcholine receptors: a validation study using the acetylcholine binding protein.Concatenated nicotinic acetylcholine receptors: A gift or a curse?Discovery of novel α₁-adrenoceptor ligands based on the antipsychotic sertindole suitable for labeling as PET ligands.Engineered α4β2 nicotinic acetylcholine receptors as models for measuring agonist binding and effect at the orthosteric low-affinity α4-α4 interface.Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors.Open3DALIGN: an open-source software aimed at unsupervised ligand alignment.Open3DQSAR: a new open-source software aimed at high-throughput chemometric analysis of molecular interaction fields.Design, synthesis, and biological evaluation of Erythrina alkaloid analogues as neuronal nicotinic acetylcholine receptor antagonists.Brute-force pharmacophore assessment and scoring with Open3DQSAR.Modeling and mutational analysis of the binding mode for the multimodal antidepressant drug vortioxetine to the human 5-HT3A receptor5-(Piperidin-4-yl)-3-Hydroxypyrazole: A Novel Scaffold for Probing the Orthosteric γ-Aminobutyric Acid Type A Receptor Binding SiteSynthesis and pharmacological evaluation of 6-aminonicotinic acid analogues as novel GABAA receptor agonistsSynthesis and Biological Evaluation of 4-(Aminomethyl)-1-hydroxypyrazole Analogues of Muscimol as γ-Aminobutyric AcidA Receptor AgonistsConformationally restrained carbamoylcholine homologues. Synthesis, pharmacology at neuronal nicotinic acetylcholine receptors and biostructural considerationsNovel Approach for the Search for Chemical Scaffolds with Dual Activity with Acetylcholinesterase and the α7 Nicotinic Acetylcholine Receptor-A Perspective for the Treatment of Neurodegenerative DisordersSDF2XYZ2SDF: how to exploit TINKER power in cheminformatics projectsCovalent attachment of antagonists to the α7 nicotinic acetylcholine receptor: synthesis and reactivity of substituted maleimidesFrom shellfish poisoning to neuroscienceGalantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptorsProbing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptorsFunctional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophicConcatenated γ-aminobutyric acid type A receptors revisited: Finding order in chaosRevisiting autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) mutations in the nicotinic acetylcholine receptor reveal an increase in efficacy regardless of stochiometry
P50
Q26774441-37A3779A-E4EA-439C-9109-5CC734F4A08FQ27682262-F647B903-FFE7-4B26-9DF9-36AE47DE938EQ27683619-4AA30F76-CBAF-4274-8179-69D1A88595FBQ27701563-87B5D0E8-506B-4ABD-BBFC-1A3555815FC5Q28655994-E91528DA-DBFF-4DE4-A7A8-48E1DCD90FA6Q34139233-272313C8-9FD4-4373-BC90-0C3E58090710Q36110375-D739573D-DE11-4B12-8E20-8DE11908B5FAQ37168375-E82BC3DF-0DFE-4ABD-A31C-7BC0E6014D7CQ38173266-B971B0AB-6DD7-4A25-96BE-CC5166DE5C37Q38233283-5E00B0A5-027F-4505-AC30-CB5D4E9327F9Q38323703-D15717B8-25E6-4CE2-9A02-EC94A20EF228Q38634293-D6D8E9F4-3756-4106-B4B7-1BE77C1A61AFQ39394319-1E3A074A-02E0-497F-B60D-0150D30388D7Q40151264-F7B326EA-0E56-470F-B7E2-46F192FCA831Q40613572-2CA70C0E-1FEA-4C56-AAAB-E0F9F8E6F896Q40737855-85B3BF43-3C3F-4DFB-8F86-398E5DF677B8Q42123087-8D029AAD-FA34-4DD7-9E6A-BF53DC32E959Q42872695-452394B9-1342-4F8B-9D20-945E12586CDBQ47703691-6DDB2BC2-C34D-4AEC-9E3C-F47F766D3EADQ48263945-47B7419D-CDFB-413F-8E9A-59553F92DE73Q48373654-5CF66884-7C89-43D2-A5B4-2B61E548681CQ48667658-3DB9D848-7E8F-4B6B-85B3-DAC12165879AQ51544926-B270B4B3-62C8-4BA0-BC2A-9DC38BF9DA8DQ51705465-C875A297-330B-407E-906C-FB66B668F5DDQ54667276-57F27BEB-3576-44E2-9545-4A4AAEC3E673Q54919067-57B832BF-91C9-49C3-93B1-D3996C1082E8Q57149531-44386E7A-6676-4F5B-A21E-88B0642A0E52Q61998279-88B3F657-8DF1-43E6-9EB4-53092E7297BDQ61998288-FB340442-A744-4A8D-9EBF-F76E2AC38B1AQ61998300-9FBA749A-9D80-41C0-8F82-15C1B5AA123DQ62065479-3D43585B-0C82-4896-8E95-1F80127D19FEQ64268861-9B7F1F49-A065-4B4E-9662-58C1C357A98AQ84107239-05C6F198-8E24-4868-8B8D-0EB1686DE109Q84212832-F7A7A4C7-B994-42F9-91C8-4C0AA60D7102Q85287155-EE1534A2-317C-48AD-AF79-FA1E70987823Q88399016-86C5B1C1-D3FC-45BA-AB90-1B5A818F20A9Q91018846-104A03B2-D91E-4FAF-99EB-A82F78A7FB33Q91386446-7C9D7072-F177-4BAB-9747-B4CF543E8142Q93109803-C2689FDF-ED8C-4E78-B2A9-8874FD15FFF0Q93346063-345A123E-8FFA-41A7-BE50-902A92D3BABF
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Thomas Balle
@en
Thomas Balle
@nl
type
label
Thomas Balle
@en
Thomas Balle
@nl
prefLabel
Thomas Balle
@en
Thomas Balle
@nl
P31
P496
0000-0002-0233-8350